Show simple item record

Early Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults

dc.rights.licenseopenen_US
dc.contributor.authorDESCHAMPS, Romain
dc.contributor.authorGUILLAUME, Jessica
dc.contributor.authorCIRON, Jonathan
dc.contributor.authorAUDOIN, Bertrand
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorRUET, Aurélie
dc.contributor.authorMAILLART, Elisabeth
dc.contributor.authorPIQUE, Julie
dc.contributor.authorBENYAHYA, Lakhdar
dc.contributor.authorLAPLAUD, David
dc.contributor.authorMICHEL, Laure
dc.contributor.authorCOLLONGUES, Nicolas
dc.contributor.authorCOHEN, Mikael
dc.contributor.authorAYRIGNAC, Xavier
dc.contributor.authorTHOUVENOT, Eric
dc.contributor.authorZEPHIR, Helene
dc.contributor.authorBOURRE, Bertrand
dc.contributor.authorFROMENT TILIKETE, Caroline
dc.contributor.authorMOREAU, Thibault
dc.contributor.authorCANTAGREL, Paul
dc.contributor.authorKERSCHEN, Philippe
dc.contributor.authorCABASSON, Sebastien
dc.contributor.authorMAUBEUGE, Nicolas
dc.contributor.authorHANKIEWICZ, Karolina
dc.contributor.authorNIFLE, Chantal
dc.contributor.authorBERGER, Eric
dc.contributor.authorMEGHERBI, Hana
dc.contributor.authorMAGY, Laurent
dc.contributor.authorKLAPCZYNSKI, Frederic
dc.contributor.authorSAROV RIVIERE, Mariana
dc.contributor.authorGIANNESINI, Claire
dc.contributor.authorHAMELIN, Lorraine
dc.contributor.authorGIROUX, Marianne
dc.contributor.authorBRANGER, Pierre
dc.contributor.authorMAUROUSSET, Aude
dc.contributor.authorMATHEY, Guillaume
dc.contributor.authorMOULIN, Maximilien
dc.contributor.authorMÉLÉ, Nicolas
dc.contributor.authorPAPEIX, Caroline
dc.contributor.authorMARIGNIER, Romain
dc.date.accessioned2025-04-29T15:30:55Z
dc.date.available2025-04-29T15:30:55Z
dc.date.issued2024-08-13
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206491
dc.description.abstractEnBackground and objectives: Because myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a recently identified autoimmune disorder, the natural history of MOGAD is still not well described. The objective of this study was to describe the long-term outcomes of adult patients with MOGAD. In addition, we aimed to identify factors affecting relapse risk and neurologic outcomes. Methods: Clinical and biological data were obtained from patients with a first event of MOGAD and included in the French nationwide incident cohort between February 2014 and March 2017. Only patients aged 18 years or older at disease onset and with observation period of at least 3 months were included. Data were collected prospectively until July 2023 and registered in the dedicated French nationwide database. This form includes every relapse with phenotype description during follow-up, date of last assessment, final clinical outcome with Expanded Disability Status Scale score and visual acuity, and maintenance therapy. The probability of recurrence-free survival was assessed using the Kaplan-Meier method. Results: We included 128 patients. The onset phenotype was isolated optic neuritis in 81 patients (63.3%) and isolated myelitis in 25 patients (19.5%). The median follow-up duration was 77.8 months (range 3.2-111.2), with 49 patients (38.3%) experienced at least one relapse. Median times from onset to second and third attacks were 3.2 (1.0-86.2) and 13.0 (2.6-64.4) months, respectively. At the last assessment, Expanded Disability Status Scale Score was ≥3 and ≥6 in 22 (17.2%) and 6 (4.7%) patients, respectively. Eighty patients received at least one maintenance treatment. This treatment was initiated after the first attack in 47 patients (36.7% of the whole cohort) and at the time of a second attack in 25 (19.5%). Multivariate analysis revealed that initiating maintenance treatment after the first attack was associated with a lower relapse risk (OR = 0.26 [95% CI 0.11-0.62], p = 0.002). In patients receiving maintenance therapy after first attack, the 2-year, 4-year, 6-year, and 8-year relapse risks were 11%, 15%, 20%, and 20%, respectively. In other patients, the risks were 41%, 46%, 51%, and 56%. Discussion: The highest risk of a relapse in MOGAD occurs early, and initiating maintenance therapy from the first attack substantially reduced the relapse risk.
dc.description.sponsorshipObservatoire Français de la Sclérose en Plaquesen_US
dc.language.isoENen_US
dc.subject.enAdult
dc.subject.enAged
dc.subject.enAutoantibodies / blood
dc.subject.enCohort Studies
dc.subject.enFemale
dc.subject.enFollow-Up Studies
dc.subject.enFrance / epidemiology
dc.subject.enHumans
dc.subject.enMale
dc.subject.enMiddle Aged
dc.subject.enMyelin-Oligodendrocyte Glycoprotein / immunology
dc.subject.enOptic Neuritis
dc.subject.enRecurrence
dc.subject.enYoung Adult
dc.title.enEarly Maintenance Treatment Initiation and Relapse Risk Mitigation After a First Event of MOGAD in Adults
dc.title.alternativeNeurologyen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1212/WNL.0000000000209624en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed38991174en_US
bordeaux.journalNeurologyen_US
bordeaux.pagee209624en_US
bordeaux.volume103en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - U1215en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamRelations glie-neuroneen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurology&rft.date=2024-08-13&rft.volume=103&rft.issue=3&rft.spage=e209624&rft.epage=e209624&rft.au=DESCHAMPS,%20Romain&GUILLAUME,%20Jessica&CIRON,%20Jonathan&AUDOIN,%20Bertrand&RUET,%20Aur%C3%A9lie&rft.genre=article


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record